This study is testing a new treatment called azer-cel for adults with certain types of blood cancer: B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Azer-cel is a special kind of cell therapy that targets and destroys cancer cells. Patients will get the treatment through an IV (intravenous) infusion, which means it goes directly into their vein. Before receiving azer-cel, patients will have a procedure called lymphodepletion to prepare their body. The study will check if the treatment is safe and how well it works. Patients will be watched closely for two years and then followed up for up to 15 years.

• The study involves multiple visits over a long period.
• Participants will be closely monitored for side effects and treatment effectiveness.
• There may be risks associated with the treatment and the procedures involved.